A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)
Sponsor: |
Kite Pharma, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAR9001 |
U.S. Govt. ID: |
NCT03105336 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after a 3 day course of chemotherapy, is safe and effective in treating relapsed or refractory (r/r) indolent non-Hodgkin B-cell lymphoma (iNHL). KTE-C19 is made from white blood cells that are removed from the individual. A virus (retrovirus) is used to introduce a gene that creates a protein (called a chimeric antigen receptor or CAR) on the surface of T cells, a type of blood cell that fights infection and eliminates cancer cells. The hope is that the CAR on the T cells will bind to and kill cells that express CD19, a protein that is found on B-cell lymphomas.
This study is closed
Investigator
Ran Reshef, MD
Are you 18 years of age or older? |
Yes |
No |
Have you been diagnosed with indolent non-Hodgkin B-cell lymphoma such as follicular lymphoma? |
Yes |
No |
Have you received at least 2 lines of therapy for your indolent lymphoma? |
Yes |
No |